WALTHAM, Mass.--(BUSINESS WIRE)--July 14, 2008--PerkinElmer, Inc. (NYSE: PKI), a leader in Health Sciences and Photonics, today announced that Alan Fletcher, Ph.D., has joined the Company as vice president, business development for PerkinElmer's Life and Analytical Sciences business. In this role, Fletcher will be responsible for growing the Bio-discovery business through the development of strategic partnerships and alliances in the life science research area, and the introduction of new technologies for GPCR, kinase and biomarker drug target classes.
Fletcher brings nearly 20 years of operational, technical and commercial experience in the drug discovery and life science industries to his new position. "Alan's arrival is an important next step in the growth of our Bio-discovery business," said Richard Eglen, Ph.D., president, Bio-discovery, PerkinElmer. "He brings both strong expertise in technology and drug discovery, as well as proven leadership qualities that will be instrumental in further positioning PerkinElmer as the industry's leading provider of cellular screening and drug discovery reagent technologies and services."
"I am very happy to be joining PerkinElmer and am looking forward to contributing to the Company's long-term success in drug discovery and research," said Fletcher.
Fletcher joins PerkinElmer from GE Healthcare where he held multiple positions in the company's life science and discovery systems business units. Prior to this, Fletcher held a range of leadership roles within consumer products, biotechnology, R&D, and technology transfer for a number of Fortune 500 corporations, where he gained extensive experience in business development, commercialization of biological and chemical research, strategy development, and technology assessment and development.
Fletcher has a doctorate in biochemical pharmacology from the University of London in the United Kingdom. He has been published widely in the areas of drug discovery and high throughput screening, and has served as a member of the board of directors for the Society of Biomolecular Sciences (SBS) since 2002 and as chairman of the board in 2005.
PerkinElmer's Bio-discovery business provides the most comprehensive offering of enabling technologies and services including biochemistry, detection systems, cell imaging, and liquid handling to accelerate life sciences research, from drug discovery to academic research.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through http://www.perkinelmer.com or 1-877-PKI-NYSE.